Metastatic Castration Resistant Prostate Cancer (mCRPC) Clinical Trial
Official title:
Real World Evidence Study on Metastatic Prostate Cancer Patient Characteristics, Treatment Patterns and Outcomes in the Pirkanmaa Hospital District in Finland
| Verified date | April 2024 |
| Source | Pfizer |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Observational |
Comprehensive understanding of the epidemiology and disease burden of metastatic prostate cancer patients in Finland is lacking. This study will address the following questions: - What are the demographic and clinical characteristics of metastatic prostate cancer patients? - How are metastatic prostate cancer patients currently treated and how effective are these treatments? - How does the development of castration-resistance affect patient outcomes? - What is the economic burden of metastatic prostate cancer?
| Status | Completed |
| Enrollment | 1 |
| Est. completion date | April 10, 2024 |
| Est. primary completion date | April 10, 2024 |
| Accepts healthy volunteers | No |
| Gender | Male |
| Age group | 18 Years and older |
| Eligibility | Inclusion Criteria: - Diagnosis of prostate cancer between 1/1/2007 - 12/31/2022 - Resident of Pirkanmaa at index date (diagnosis of mCSPC and/or mCRPC) - Detection of metastatic prostate cancer Exclusion Criteria: - Prevalent mCSPC and mCRPC patients (mCSPC or mCRPC diagnosis date before 1/1/2014 - Patient has another cancer diagnosis or the patient has received chemotherapy other than docetaxel or cabazitaxel within 2 years of mPC diagnosis. |
| Country | Name | City | State |
|---|---|---|---|
| Finland | Pfizer | Helsinki |
| Lead Sponsor | Collaborator |
|---|---|
| Pfizer |
Finland,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Characteristics of Metastatic Cancer Patients | Demographical and clinical variables of patients will be summarized | up to 12 years | |
| Primary | Number of treatments received for metastatic prostate cancer | up to 12 years | ||
| Primary | Overall Survival (OS) | up to 12 years | ||
| Primary | Time to next treatment (TTNT) | up to 12 years | ||
| Secondary | Time of disease progression from castration sensitive to castration resistant | up to 12 years | ||
| Secondary | Identify factors associated with disease progression to castration resistant | Up to 12 years | ||
| Secondary | The number of patients per treatment type | up to 12 years | ||
| Secondary | Incidence of metastatic prostate cancer (mPC) | Up to 12 years | ||
| Secondary | Incidence of metastatic castration sensitive prostate cancer (mCSPC) | up to 12 years | ||
| Secondary | Incidence of metastatic castration resistant prostate cancer (mCRPC) | up to 12 years | ||
| Secondary | Health Care resource utilization (HCRU): number of outpatient clinic visits, hospitalization and hospital inpatient days | up to 12 years |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT05208229 -
The Role of WB-MRI in the Evaluation of Prostate Cancer Patients Treated With Lutetium - Prostate Specific Membrane Antigen (Lu-PSMA)
|
||
| Suspended |
NCT05425862 -
Pidnarulex and Talazoparib in Patients With Metastatic Castration Resistant Prostate Cancer
|
Phase 1 | |
| Active, not recruiting |
NCT03480646 -
ProSTAR: A Study Evaluating CPI-1205 in Patients With Metastatic Castration Resistant Prostate Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03874884 -
177Lu-PSMA-617 Therapy and Olaparib in Patients With Metastatic Castration Resistant Prostate Cancer
|
Phase 1 | |
| Terminated |
NCT03549000 -
A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.
|
Phase 1 | |
| Terminated |
NCT04052204 -
Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03724747 -
Study to Evaluate the Safety, Tolerability,Pharmacokinetics, and Antitumor Activity of a Thorium-227 Labeled Antibody-chelator Conjugate Alone and in Combination With Darolutamide, in Patients With Metastatic Castration Resistant Prostate Cancer
|
Phase 1 | |
| Completed |
NCT04516161 -
EPIX, a Study to Gather More Information About Characteristics of Patients and Other Factors Which May Contribute to Survival Over a Long Period of Time in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Treated With Radium-223 (Xofigo)
|
||
| Withdrawn |
NCT02130947 -
Exercise Intervention for Pts With Metastatic Castration-Resistant Prostate Cancer Receiving Abiraterone or Enzalutamide
|
N/A |